BMS gets the ball rolling on liso-cel in Europe; BeiGene files China NDA for in-house PARP drug
→ The EMA has validated Bristol Myers Squibb’s marketing application for liso-cel, its CAR-T that’s been held up at the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
